CA2275033A1 - Biodegradable targetable microparticle delivery system - Google Patents

Biodegradable targetable microparticle delivery system Download PDF

Info

Publication number
CA2275033A1
CA2275033A1 CA002275033A CA2275033A CA2275033A1 CA 2275033 A1 CA2275033 A1 CA 2275033A1 CA 002275033 A CA002275033 A CA 002275033A CA 2275033 A CA2275033 A CA 2275033A CA 2275033 A1 CA2275033 A1 CA 2275033A1
Authority
CA
Canada
Prior art keywords
acid subunits
alpha
amino acid
lactide
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002275033A
Other languages
French (fr)
Other versions
CA2275033C (en
Inventor
Kenneth K. Sokoll
Pele Chong
Michel H. Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Connaught Laboratories Limited
Kenneth K. Sokoll
Pele Chong
Michel H. Klein
Aventis Pasteur Limited/Aventis Pasteur Limitee
Sanofi Pasteur Limited/Sanofi Pasteur Limitee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25089888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2275033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Laboratories Limited, Kenneth K. Sokoll, Pele Chong, Michel H. Klein, Aventis Pasteur Limited/Aventis Pasteur Limitee, Sanofi Pasteur Limited/Sanofi Pasteur Limitee filed Critical Connaught Laboratories Limited
Publication of CA2275033A1 publication Critical patent/CA2275033A1/en
Application granted granted Critical
Publication of CA2275033C publication Critical patent/CA2275033C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6852—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

Copolymers designed for use as particulate carriers containing functionalizable amino acid subunits for coupling with targeting ligands are described. The copolymers are polyesters composed of .alpha.-hydroxy acid subunits such as D,L-lactide and pseudo-.alpha.-amino acid subunits which may be derived from serine or terpolymers of D,L-lactide <1 M G>
and glycolide and pseudo-.alpha.-amino acid subunits which may be derived from serine. Stable vaccine preparations useful as delayed release formulations containing antigen or antigens and adjuvants encapsulated within or physically mixed with polymeric microparticles are described. The particulate carriers are useful for delivering agents to the immune system of a subject by mucosal or parenteral routes to produce immune responses, including antibody and protective responses.
CA002275033A 1996-12-20 1997-12-19 Biodegradable targetable microparticle delivery system Expired - Fee Related CA2275033C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/770,850 US6042820A (en) 1996-12-20 1996-12-20 Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US08/770,850 1996-12-20
PCT/CA1997/000980 WO1998028357A1 (en) 1996-12-20 1997-12-19 Biodegradable targetable microparticle delivery system

Publications (2)

Publication Number Publication Date
CA2275033A1 true CA2275033A1 (en) 1998-07-02
CA2275033C CA2275033C (en) 2005-08-02

Family

ID=25089888

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002275033A Expired - Fee Related CA2275033C (en) 1996-12-20 1997-12-19 Biodegradable targetable microparticle delivery system

Country Status (13)

Country Link
US (7) US6042820A (en)
EP (1) EP0946624B1 (en)
JP (3) JP3242118B2 (en)
AT (1) ATE236207T1 (en)
AU (1) AU729305B2 (en)
BR (1) BR9714065A (en)
CA (1) CA2275033C (en)
DE (1) DE69720516T2 (en)
DK (1) DK0946624T3 (en)
ES (1) ES2196385T3 (en)
NZ (1) NZ336718A (en)
PT (1) PT946624E (en)
WO (1) WO1998028357A1 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801288D0 (en) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and method of production
KR20010088302A (en) 1998-06-19 2001-09-26 추후 제출 LT and CT in parenteral immunization methods against helicobacter infection
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
PT1295611E (en) * 2000-06-20 2010-09-14 Dainippon Sumitomo Pharma Co Oligonucleotide-transferring preparations
EP1301204A1 (en) * 2000-07-05 2003-04-16 Merieux OraVax SNC Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US10398830B2 (en) * 2000-11-17 2019-09-03 Vactronix Scientific, Llc Device for in vivo delivery of bioactive agents and method of manufacture thereof
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
WO2002060486A2 (en) * 2001-01-29 2002-08-08 Fresco Bernard B Controlled release microsphere system for administration of drug to the eye
KR100888566B1 (en) * 2001-06-20 2009-03-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Method of promoting nucleic acid transfer
EP1438413A4 (en) * 2001-10-03 2006-06-07 Selective Genetics Inc Traversal of nucleic acid molecules through a fluid space and expression in repair cells
WO2003030879A1 (en) * 2001-10-05 2003-04-17 Surmodics, Inc. Particle immobilized coatings and uses thereof
US7838619B2 (en) * 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
WO2003062199A2 (en) * 2002-01-16 2003-07-31 Agency For Disease Diagnosis And Prevention Pace-a microspheres for delivery of antigens
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
FR2839260B1 (en) * 2002-05-03 2005-02-25 Inst Nat Sante Rech Med MICROPARTICLES BASED ON BICOMPATIBLE AND BIODEGRADABLE MATERIAL SUPPORTING CELLS AND BIOLOGICALLY ACTIVE SUBSTANCES
US20050129776A1 (en) 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
AU2003237528A1 (en) * 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
US20040170606A1 (en) * 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
US20040142887A1 (en) * 2002-07-10 2004-07-22 Chengji Cui Antigen-polymer compositions
AU2003282372A1 (en) * 2002-11-29 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparation of biodegradable polymers and resins from proteins, and plastics obtained thereby
EP1616957B1 (en) 2003-04-18 2017-05-17 National Cerebral and Cardiovascular Center Vector
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
JP2005154514A (en) * 2003-11-21 2005-06-16 Univ Waseda Functional biodegradable material and its manufacturing method
JP4954550B2 (en) * 2003-12-19 2012-06-20 大日本住友製薬株式会社 Novel nucleic acid introduction method
AU2005244128B2 (en) * 2004-05-07 2009-06-25 President And Fellows Of Harvard College Pulmonary malarial vaccine
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
JP2009530457A (en) * 2006-03-21 2009-08-27 ディーエスエム アイピー アセッツ ビー．ブイ． Fine particles containing crosslinked polymer
CN101511347B (en) * 2006-08-31 2012-11-28 Sk化学株式会社 Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby
WO2008144591A2 (en) 2007-05-16 2008-11-27 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
US8551072B2 (en) 2007-12-12 2013-10-08 Boston Scientific Scimed, Inc. Methods, devices and compositions for controlled drug delivery to injured myocardium
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2361098B1 (en) 2008-10-31 2019-08-28 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
KR101181563B1 (en) * 2008-11-14 2012-09-10 에스케이케미칼주식회사 Method for preparing microspheres and microspheres produced thereby
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
EP2756845B1 (en) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
AU2010254549B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
WO2011041385A2 (en) 2009-09-29 2011-04-07 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
US20130101609A1 (en) * 2010-01-24 2013-04-25 Novartis Ag Irradiated biodegradable polymer microparticles
WO2011115882A1 (en) 2010-03-15 2011-09-22 Boston Scientific Scimed, Inc. Drug eluting stents and methods of making the same
MX2012013713A (en) 2010-05-26 2013-01-28 Selecta Biosciences Inc Nanocarrier compositions with uncoupled adjuvant.
WO2012054718A2 (en) 2010-10-22 2012-04-26 The General Hospital Corporation Treating long qt syndrome
WO2012065182A2 (en) 2010-11-12 2012-05-18 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
DE102011018499A1 (en) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin
EA201490381A1 (en) 2011-07-29 2014-06-30 Селекта Байосайенсиз, Инк. SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL)
JP2014533953A (en) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Therapeutic RNA switch compositions and methods of use
US9534059B2 (en) 2012-04-13 2017-01-03 Children's Medical Center Corporation TIKI inhibitors
US10159746B2 (en) 2012-05-08 2018-12-25 Onyx Therapeutics, Inc. Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
EP2851086A1 (en) 2013-09-20 2015-03-25 Sanofi Serpins: methods of therapeutic ß-cell regeneration and function
EP2769732A1 (en) 2013-02-22 2014-08-27 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
WO2014159878A2 (en) 2013-03-13 2014-10-02 Regents Of The University Of California Intranasal administration of guanidinylated aminoglycosides
DK2970225T3 (en) 2013-03-14 2018-09-24 Onyx Therapeutics Inc DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
US9737525B2 (en) 2013-06-07 2017-08-22 The General Hospital Corporation Small molecule activators of NRF2 pathway
WO2015034996A1 (en) 2013-09-06 2015-03-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
EP2994175A1 (en) 2014-02-04 2016-03-16 Abbott Cardiovascular Systems, Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
US10179775B2 (en) 2014-08-11 2019-01-15 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
JO3474B1 (en) 2014-08-29 2020-07-05 Amgen Inc Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
WO2016077240A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
EP3218373B1 (en) 2014-11-10 2020-07-22 Evrys Bio, LLC Anti-hcmv compositions and methods
WO2016077382A2 (en) 2014-11-11 2016-05-19 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
WO2016100401A1 (en) 2014-12-15 2016-06-23 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
ES2808750T3 (en) 2015-04-03 2021-03-01 Univ Massachusetts Oligonucleotide compounds targeting huntingtin mRNA
EP3995581A3 (en) 2015-04-03 2022-10-26 University of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EP3356415A1 (en) 2015-09-29 2018-08-08 Amgen Inc. Asgr inhibitors
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
AU2016359629B2 (en) 2015-11-23 2023-03-09 Ranjan BATRA Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
AU2017210726B2 (en) 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
JP6453507B2 (en) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Compound that inhibits MCL-1 protein
JP7398279B2 (en) 2017-05-10 2023-12-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Targeted editing of cellular RNA by CRISPR/CAS9 nuclear delivery
US20210128702A1 (en) 2017-08-11 2021-05-06 Dana-Farber Cancer Institute, Inc. Use of a botulinum toxin agent for treating plasma cell disorders
EP3668968A1 (en) 2017-08-14 2020-06-24 Sanford Burnham Prebys Medical Discovery Institute Cardiogenic mesoderm formation regulators
EP3668878A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Compounds that inhibit mcl-1 protein
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences Amide substituted thiazoles as protein secretion inhibitors
EP3697783A4 (en) 2017-10-18 2023-04-26 Evrys Bio, LLC Broad spectrum antiviral compositions and methods
US11413288B2 (en) 2017-11-01 2022-08-16 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
WO2019173181A1 (en) 2018-03-05 2019-09-12 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
CN112424352A (en) 2018-05-11 2021-02-26 阿尔法阿诺麦里克公司 Oligonucleotide conjugates comprising 7 '-5' -alpha-anomeric bicyclic sugar nucleosides
KR20210093227A (en) 2018-08-10 2021-07-27 유니버시티 오브 매사추세츠 Modified oligonucleotides targeting SNPs
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
BR112021012172A2 (en) 2018-12-12 2021-08-31 Kite Pharma, Inc. CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE
WO2020176863A1 (en) 2019-02-28 2020-09-03 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors
WO2020227395A2 (en) 2019-05-06 2020-11-12 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
CN110423338B (en) * 2019-08-12 2021-05-25 深圳市氩氪新材料技术研究服务有限公司 Preparation method of modified polylactic acid material
IL300736A (en) 2020-08-31 2023-04-01 Kezar Life Sciences Protein secretion inhibitors
AU2022299169A1 (en) 2021-06-23 2024-02-08 Beth Israel Deaconess Medical Center, Inc. Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
WO2023164250A1 (en) 2022-02-28 2023-08-31 Kezar Life Sciences Sec61 inhibitors and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30170A (en) * 1860-09-25 Improvement in plows
US2676945A (en) 1950-10-18 1954-04-27 Du Pont Condensation polymers of hydroxyacetic acid
US3839297A (en) 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
USRE30170E (en) 1975-04-04 1979-12-18 Sutures, Inc. Hydrolyzable polymers of amino acid and hydroxy acids
DE3521994A1 (en) 1985-06-20 1987-01-02 Bayer Ag N- (2-AMINOACYLAMIDO-2-DESOXY-HEXOSYL) -AMIDES, CARBAMATES AND UREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US5248761A (en) * 1992-08-12 1993-09-28 United States Surgical Corporation Amino acid terminated polyesters having predetermined monomeric sequence
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5593778A (en) * 1993-09-09 1997-01-14 Kanebo, Ltd. Biodegradable copolyester, molded article produced therefrom and process for producing the molded article
WO1995018781A1 (en) * 1994-01-06 1995-07-13 Metabolix, Inc. Methods for synthesizing oligomers containing hydroxy acid units

Also Published As

Publication number Publication date
EP0946624B1 (en) 2003-04-02
US6228423B1 (en) 2001-05-08
US6623764B1 (en) 2003-09-23
ATE236207T1 (en) 2003-04-15
ES2196385T3 (en) 2003-12-16
DE69720516D1 (en) 2003-05-08
JP3428972B2 (en) 2003-07-22
BR9714065A (en) 2000-10-24
PT946624E (en) 2003-08-29
US6042820A (en) 2000-03-28
JP3242118B2 (en) 2001-12-25
US6312732B1 (en) 2001-11-06
JP3990303B2 (en) 2007-10-10
US6471996B1 (en) 2002-10-29
DE69720516T2 (en) 2004-02-19
WO1998028357A1 (en) 1998-07-02
JP2003261661A (en) 2003-09-19
AU729305B2 (en) 2001-02-01
US6287604B1 (en) 2001-09-11
JP2002138139A (en) 2002-05-14
NZ336718A (en) 2001-01-26
US20050163745A1 (en) 2005-07-28
AU5472198A (en) 1998-07-17
EP0946624A1 (en) 1999-10-06
CA2275033C (en) 2005-08-02
DK0946624T3 (en) 2003-07-14
JP2000509428A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
CA2275033A1 (en) Biodegradable targetable microparticle delivery system
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP0978566A3 (en) Chimaeric adenoviruses
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
CA2172507A1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
CA2123580A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
IL150602A0 (en) Proteosome influenza vaccine
CA2354034A1 (en) Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period
WO2003007869A3 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
DK0686030T3 (en) Microparticles loaded with antigen and pharmaceutical compositions containing these microparticles
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO2004005325A3 (en) Antigen-polymer compositions
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
Sobrino et al. Synthetic peptide vaccines: foot-and-mouth disease virus as a model
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
DK1035133T3 (en) Fusion proteins comprising carriers that can induce a dual immune response
WO2001010469A3 (en) Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
EP1557466A4 (en) Tumor antigen protein and utilization thereof
CA2128247A1 (en) Vaccines based on streptokinase
IL122829A0 (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
EP1027895A3 (en) Erysipelothrix rhusiopathiae antigens and vaccine compositions
PL331792A1 (en) Aviadenovirus, nucleic acid sequence encoding an antigen determinant, host cell transformed by such sequence, antibody or immune serum reacting with such antigen determinant and vaccine against diseases associated with a novel adenovirus
ATE374622T1 (en) GENETIC VACCINES WITH ADJUVANS
DE60133102D1 (en)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141219